Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $81
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad maintains an Overweight rating on Dr Reddy's Laboratories (NYSE:RDY) and raises the price target from $80 to $81.
May 08, 2024 | 6:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Dr Reddy's Laboratories and raises the price target to $81.
The upgrade in price target by Barclays, a major financial institution, reflects a positive outlook on Dr Reddy's Laboratories' stock. This is likely to instill confidence among investors, potentially leading to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100